

National Board of Examinations

Question Paper Name :	DrNB Vascular Surgery Paper1
Subject Name :	DrNB Vascular Surgery Paper1
Creation Date :	2023-04-25 11:44:30
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB Vascular Surgery Paper1

Group Number :	1
Group Id :	3271871643
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB Vascular Surgery Paper1

Section Id :	3271871646
Section Number :	1
Section type :	Offline

Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271871650
Question Shuffling Allowed :	No
Is Section Default? :	null

Question Number : 1 Question Id : 32718721143 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

1. a) Cohort and case control studies. [5]
- b) Methods to study uncommon vascular diseases. [5]

Question Number : 2 Question Id : 32718721144 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Discuss about lymphangiogenesis. [5]
- b) Classification of lymphedema and discuss about primary lymphedema. [5]

Question Number : 3 Question Id : 32718721145 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Biological effects of smoking on the vascular system. [5]

b) Smoking cessation therapies. [5]

Question Number : 4 Question Id : 32718721146 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Development of inferior vena cava. [5]

b) Explain the various sites of Non Thrombotic Iliac Vein Lesions NIVL. [5]

Question Number : 5 Question Id : 32718721147 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Pharmacologic and nonpharmacological therapy for dyslipidemia. [5]

b) Clinical trials of management of dyslipidemia in PAD. [5]

Question Number : 6 Question Id : 32718721148 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Recommended radiographic filming projections for optimal branch separation. [5]

b) Current indications for and relative Contraindications to Venography. [5]

Question Number : 7 Question Id : 32718721149 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Pathogenesis of renovascular hypertension. [5]

b) Medical management of renovascular hypertension. [5]

Question Number : 8 Question Id : 32718721150 Question Type : SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Endovascular Access site complications. [5]
- b) Percutaneous closure device complications. [5]

Question Number : 9 Question Id : 32718721151 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Discuss about plethysmography for venous assessment. [5]
- b) Inferior vena cava Filter complications. [5]

Question Number : 10 Question Id : 32718721152 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Mechanism of action of antiplatelet drugs. [5]
- b) Newer antiplatelet agents. [5]